company background image
MGFR

MagForce OTCPK:MGFR.F Stock Report

Last Price

€2.25

Market Cap

€58.0m

7D

n/a

1Y

-53.6%

Updated

13 May, 2022

Data

Company Financials +
MGFR.F fundamental analysis
Snowflake Score
Valuation6/6
Future Growth5/6
Past Performance3/6
Financial Health0/6
Dividends0/6

MGFR.F Stock Overview

MagForce AG operates in the field of nanotechnology-based cancer therapy in Germany and Poland.

MagForce Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for MagForce
Historical stock prices
Current Share Price€2.25
52 Week High€4.80
52 Week Low€2.25
Beta2.1
1 Month Changen/a
3 Month Changen/a
1 Year Change-53.61%
3 Year Change-57.41%
5 Year Change-74.86%
Change since IPO-73.53%

Recent News & Updates

Shareholder Returns

MGFR.FUS Medical EquipmentUS Market
7Dn/a-2.3%-2.5%
1Y-53.6%-15.6%-10.4%

Return vs Industry: MGFR.F underperformed the US Medical Equipment industry which returned -17.5% over the past year.

Return vs Market: MGFR.F underperformed the US Market which returned -10.8% over the past year.

Price Volatility

Is MGFR.F's price volatile compared to industry and market?
MGFR.F volatility
MGFR.F Average Weekly Movementn/a
Medical Equipment Industry Average Movement10.1%
Market Average Movement7.8%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: Insufficient data to determine MGFR.F's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine MGFR.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199734Ben Lippshttps://www.magforce.com

MagForce AG operates in the field of nanotechnology-based cancer therapy in Germany and Poland. It offers NanoTherm, a therapy for the treatment of solid tumors; NanoPlan, a simulation software that helps the treating physicians to define the NanoTherm therapy schedule according to the distribution of the NanoTherm depots in the tumor; and NanoActivator, a magnetic field applicator. MagForce AG was founded in 1997 and is headquartered in Berlin, Germany.

MagForce Fundamentals Summary

How do MagForce's earnings and revenue compare to its market cap?
MGFR.F fundamental statistics
Market Cap€55.68m
Earnings (TTM)€14.57m
Revenue (TTM)€1.27m

3.8x

P/E Ratio

43.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MGFR.F income statement (TTM)
Revenue€1.27m
Cost of Revenue€808.15k
Gross Profit€461.21k
Other Expenses-€14.11m
Earnings€14.57m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Jun 30, 2022

Earnings per share (EPS)0.49
Gross Margin36.33%
Net Profit Margin1,147.78%
Debt/Equity Ratio86.3%

How did MGFR.F perform over the long term?

See historical performance and comparison

Valuation

Is MagForce undervalued compared to its fair value and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: MGFR.F ($2.25) is trading below our estimate of fair value ($8.42)

Significantly Below Fair Value: MGFR.F is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MGFR.F is good value based on its PE Ratio (3.8x) compared to the US Medical Equipment industry average (32.7x).

PE vs Market: MGFR.F is good value based on its PE Ratio (3.8x) compared to the US market (15.3x).


Price to Earnings Growth Ratio

PEG Ratio: MGFR.F is good value based on its PEG Ratio (0.1x)


Price to Book Ratio

PB vs Industry: MGFR.F is good value based on its PB Ratio (1.8x) compared to the US Medical Equipment industry average (2.4x).


Future Growth

How is MagForce forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


50.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MGFR.F's forecast earnings growth (50.3% per year) is above the savings rate (1.9%).

Earnings vs Market: MGFR.F's earnings (50.3% per year) are forecast to grow faster than the US market (12.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MGFR.F's revenue (45.8% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: MGFR.F's revenue (45.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MGFR.F's Return on Equity is forecast to be low in 3 years time (3.2%).


Past Performance

How has MagForce performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


45.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MGFR.F has a large one-off gain of €24.5M impacting its June 30 2021 financial results.

Growing Profit Margin: MGFR.F became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: MGFR.F has become profitable over the past 5 years, growing earnings by 45.2% per year.

Accelerating Growth: MGFR.F has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: MGFR.F has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (19.1%).


Return on Equity

High ROE: MGFR.F's Return on Equity (47.2%) is considered outstanding.


Financial Health

How is MagForce's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: MGFR.F's short term assets (€2.1M) do not cover its short term liabilities (€11.9M).

Long Term Liabilities: MGFR.F's short term assets (€2.1M) do not cover its long term liabilities (€21.6M).


Debt to Equity History and Analysis

Debt Level: MGFR.F's net debt to equity ratio (84.1%) is considered high.

Reducing Debt: Insufficient data to determine if MGFR.F's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: Insufficient data to determine if MGFR.F's debt is well covered by operating cash flow.

Interest Coverage: Insufficient data to determine if MGFR.F's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is MagForce current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MGFR.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MGFR.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MGFR.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MGFR.F's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MGFR.F has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.1yrs

Average management tenure


CEO

Ben Lipps (81 yo)

8.67yrs

Tenure

Dr. Benjamin J. Lipps, also known as Ben, serves as Director and Chief Executive Officer at MagForce USA, Inc. He has been the Chairman of the Management Board and Chief Executive Officer at MagForce AG si...


Leadership Team

Experienced Management: MGFR.F's management team is seasoned and experienced (9.1 years average tenure).


Board Members

Experienced Board: MGFR.F's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.


Top Shareholders

Company Information

MagForce AG's employee growth, exchange listings and data sources


Key Information

  • Name: MagForce AG
  • Ticker: MGFR.F
  • Exchange: OTCPK
  • Founded: 1997
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: €55.684m
  • Listing Market Cap: €57.962m
  • Shares outstanding: 29.46m
  • Website: https://www.magforce.com

Number of Employees


Location

  • MagForce AG
  • Max-Planck-Strasse 3
  • Berlin
  • Berlin
  • 12489
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/13 00:00
End of Day Share Price2022/05/10 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.